Takeaways: Skyrizi’s pediatric approval expands AbbVie’s reach in plaque psoriasis by extending its IL-23 inhibitor franchise to children and adolescents in Canada. High rates of skin clearance ...
Browsing Tag: moderate-to-severe psoriasis
Takeaways: Skyrizi’s pediatric approval expands AbbVie’s reach in plaque psoriasis by extending its IL-23 inhibitor franchise to children and adolescents in Canada. High rates of skin clearance ...